Crystalline mononapadisylate or heminapadisylate salts of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-l-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, pharmaceutical compositions comprising them and use thereof in the manufacture of medicaments for treating pulmonary disease or a condition in a mammal associated with beta-2 adrenergic receptor activity

摘要

The present disclosure relates to crystalline monoapadisylate and/or heminapadisylate salt of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one, and pharmaceutically acceptable solvates thereof. The present disclosure also relates to pharmaceutical compositions comprising the crystalline monoapadisylate and/or heminapadisylate salt of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one, and to methods of treatment comprising these pharmaceutical compositions.